Sep 26, 2023 / 06:45PM GMT
Wayne Wu - Cantor Fitzgerald - Analyst
So good afternoon. My name is Wayne Wu and I am the associate on Louise Chen's Large Cap Pharma, BioPharma & Biotech team here at Cantor. Thank you so much for joining us today with our panel presentation with PDS Biotechnology as well as Immutep. We're thrilled to have Frank as well as Marc to give us their wonderful presentations. So let's start with Frank. Thank you.
Frank Bedu-Addo - PDS Biotechnology Corporation - CEO
Thank you very much for the introduction. Let's see. How do I move this forward? Okay. Okay. So I'm just before I start, I'd just like please to advise everyone to get comfortable and be familiar with the risk factors associated with PDS and as filed with the SEC.
So who is PDS Biotechnology? We are a mid to late clinical stage biotech company developing immunotherapies that train and activate the immune system to specifically target cancer. We are developing targeted immunotherapies based on the company's proprietary, Versamune T-cell activating technology platform.
PDS Biotechnology Corp at Cantor Fitzgerald Global Healthcare Conference Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot